Multicenter, Randomized, Open-Label Trial, Assessing the Efficacy of Zidovudine, Lamivudine and Nevirapine Combination Administered Twice Daily, Versus the Association of Tenofovir, Lamivudine and Nevirapine, Once Daily, in Antiretroviral Naive HIV-1 Infected Patients
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Hiv Infection With Antiretroviral Therapy Indication
- Sponsor
- MEDEX
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- To compare the antiviral efficacy of AZT, 3TC, and NVP combination, in two doses per day, to the association of TDF, 3TC, and NVP, once a day, in antiretroviral naive HIV-1-infected patients (plasma viral load below 400 copies/ml at 96 weeks).
- Last Updated
- 20 years ago
Overview
Brief Summary
The study will compare the immuno-virological efficacy, and safety, of a once daily antiretroviral combination (tenofovir + lamivudine + nevirapine) versus a twice daily association (fixed dose combination of zidovudine/lamivudine + nevirapine) in ARV-Naive HIV-1 infected subjects, with CD4 cell count below 350/µL or below 15%, whatever the viral load. Pharmacological (nevirapine concentrations) and virologic data (resistance mutations in case of failure) will also be provided, as well as adherence rate and quality of life in respect of the treatment arms.
Detailed Description
96-week antiviral efficacy of tenofovir + lamivudine + nevirapine, once daily, versus a reference antiretroviral treatment given twice daily (zidovudine/lamivudine + nevirapine)
Investigators
Eligibility Criteria
Inclusion Criteria
- •HIV-1 infection, confirmed by a western-blot assay, at least 6 months after primary infection
- •Age \> or equal to 18 years of age
- •No prior antiretroviral treatment
- •Karnofsky superior to 60%
- •CD4 T cells \< 350/µL (2 measures, with at least a 1-month interval) in women, study will be proposed when CD4 cell count is below 250/µL, as nevirapine liver toxicity increases (X10) when CD4 are \> 250/µL
- •Written informed consent
Exclusion Criteria
- •HIV-2 infection or co-infection
- •Prior antiretroviral treatment
- •Intolerance, or contraindication to investigational drugs
- •Pregnant or breast-feeding woman, or plan to become pregnant
- •Active untreated opportunistic infections (AIDS-defining illness, category C, CDC, 1993), or malignancies requiring cytotoxic chemotherapy
- •Biological criteria: hemoglobin \< 10 G/DL, neutrophil count \< 1000/µL, platelets \< 50000/µL, creatinine \> 2N, ASAT or ALAT \> 2.5N, bilirubin \> 2N, hypophosphatemia
- •Prevision of poor adherence
- •HBC co-infection (Ag Hbs positive) or HVC co-infection (positive HCV PCR)
- •Liver failure, alcohol abuse
- •Treatment administration not recommended with investigational drugs
Outcomes
Primary Outcomes
To compare the antiviral efficacy of AZT, 3TC, and NVP combination, in two doses per day, to the association of TDF, 3TC, and NVP, once a day, in antiretroviral naive HIV-1-infected patients (plasma viral load below 400 copies/ml at 96 weeks).